Prolonging Time to Metastatic Disease, The SPARTAN Study - Matthew Smith

In this conversation with Alicia Morgans, Matthew Smith shares highlights from his 2019 European Society for Medical Oncology annual meeting, (ESMO) presentation.  He presented the updated survival results from SPARTAN, A study of apalutamide (ARN-509) in men with non-metastatic castration-resistant prostate cancer (nmCRPC), a pivotal study which led to the approval of apalutamide for men with nmCRPC. 


Matthew R. Smith, MD, Ph.D., Professor of Medicine, Harvard Medical School, Assistant in Medicine, Hematology/Oncology, Massachusetts General Hospital, Boston, Massachusetts, USA.

Alicia Morgans, MD, MPH Associate Professor of Medicine in the Division of Hematology/Oncology at the Northwestern University Feinberg School of Medicine in Chicago, Illinois, USA.


Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.